Sarepta Therapeutics's total assets for Q3 2024 were $3.60B, an increase of 5.13% from the previous quarter. SRPT total liabilities were $2.38B for the fiscal quarter, a 1.35% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.